Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00051558
Status:
COMPLETED
Last Update Posted:
2009-03-12
First Post:
2003-01-13
Brief Title:
Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Comparison of the Effects of Teriparatide With Those of Alendronate Sodium on Lumbar Spine Bone Mineral Density in Glucocorticoid-Induced Osteoporosis
Status:
COMPLETED
Status Verified Date:
2009-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Osteoporosis is a condition in which the amount of bone is reduced the bones are weak and there is an increased risk for fractures Glucocorticoids such as prednisone are prescribed to treat a large number of conditions such as arthritis and asthma When taken for several months or longer glucocorticoids can cause bone loss and lead to a form of osteoporosis called glucocorticoid-induced osteoporosis This study compared the effects of teriparatide the study drug with alendronate an approved drug for treating glucocorticoid-induced osteoporosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B3D-US-GHBZ | None | None | None |